Investigating how PKR-Bcl2 signaling can help overcome resistance to paclitaxel in ovarian cancer
Targeting PKR-Bcl2 Signaling to Overcome Paclitaxel Resistance in Ovarian Cancer
This study is looking into why some women with ovarian cancer don’t respond well to the chemotherapy drug paclitaxel, and it aims to find ways to make the treatment more effective by exploring how certain proteins in the body affect cancer cell death.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-10889047 on NIH RePORTER |
What this research studies
This research focuses on understanding why some ovarian cancer patients do not respond to paclitaxel, a common chemotherapy drug. It aims to identify specific biological markers that can predict patient responses and enhance drug sensitivity. The study will explore the role of a protein called PKR in regulating cancer cell death and how it interacts with another protein, Bcl2, to influence the effectiveness of paclitaxel. By conducting laboratory experiments, the researchers hope to develop new strategies to improve treatment outcomes for patients with drug-resistant ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are ovarian cancer patients who have shown resistance to paclitaxel treatment.
Not a fit: Patients with early-stage ovarian cancer who have not yet undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ovarian cancer patients who currently experience resistance to paclitaxel.
How similar studies have performed: Previous research has shown promising results in targeting similar signaling pathways to enhance chemotherapy effectiveness, indicating potential for success in this approach.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Dong, Jixin — University of Nebraska Medical Center
- Study coordinator: Dong, Jixin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.